Tumor Biology, Biomarkers, and Pathology

59: Genomic characterization of recurrent uRCC tumors

60: Mismatch repair (MMR), microsatellite instability (MSI), and tumor mutational burden (TMB) as predictive biomarkers for immune checkpoint inhibitors (ICI) in renal cell carcinoma (RCC).

61: The Impact of Genetic Ancestry on the Molecular Basis of Clear Cell Renal Cell Carcinoma

62: Body composition radiodensities at diagnosis may be non-invasive proxies for tumor aggressiveness and poor prognosis in non-metastatic clear cell renal cell carcinoma (ccRCC): The Resolve Study.

63: COL41A and ITGAV colocalization in immunotherapy resistant clear cell renal cell carcinoma.

64: Spatial analysis of the tumor immune cell microenvironment in papillary renal cell carcinoma

65: Biomarkers associated with Inferior Vena Cava (IVC) Thrombus in Patients (pts) with metastatic Renal Cell Carcinoma (mRCC) undergoing Cytoreductive Nephrectomy and receiving Immune Checkpoint Inhibitors (ICI)-based regimen.

66: The Distribution and Prognostic Importance of Mutations Across Tumor Size in ccRCC

68: Characterization of FOLH1 Expression in Renal Cell Carcinoma

69: Dissecting metabolic alterations of clear cell renal cell carcinomas one cell at a time

73: Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) -MRD GATE RCC